<DOC>
	<DOCNO>NCT01002508</DOCNO>
	<brief_summary>The safety efficacy vaccination influenza patient scleroderma clear . The objective study ass safety efficacy 50 patient scleroderma comparison 30 control</brief_summary>
	<brief_title>Influenza Vaccination Patients With Scleroderma</brief_title>
	<detailed_description>Fifty patient scleroderma 30 healthy , age match control participate study . After sign informed consent , subject vaccinate inactivated split virion vaccine recommend WHO fall . Patients evaluate weel 0 6 week later . Clinical evaluation base modify Rodnan score , number digital ischemic ulcer , presence gastrointestinal respiratory symptom , number swell tender joint , visual global evaluation physician , ESR CRP Blood collect day vaccination 6 week later . The immunogenicity vaccine test Haemagglutination inhibition ( HI ) test . Influenza virus two important surface glycoprotein : haemagglutinin ( HA ) neuraminidase ( NA ) . Antigenic classification subtyping influenza virus base two glycoprotein . HA play key role virus cell entry bind cell surface receptor , find also red blood cell certain specie . Binding red cell result haemagglutination , observe carpet agglutinate red cell bottom tube microtitre well . In HI test , antibody direct viral haemagglutinins block virus binding blood cell thus inhibits haemagglutination reaction . The pre- post immunization HI antibody test Central Virology Laboratory Israeli Ministry Health use HI test accord standard WHO procedure 16 . Sera separate , code label , store -20°C test . Sera treat receptor destroy enzyme cholera filtrate remove non-specific inhibitor , Turkey red blood cell remove non-specific agglutinin . The treated serum test HI test three antigen include vaccine : A/California ( CAL ) , A/Wisconsin B/Malaysia . The work dilution ( test dose ) antigen contain four haemagglutinin unit 25 µl antigen . Test dose dilute phosphate buffer saline ( PBS ) add serial dilution antiserum . The haemagglutinin inhibition titer determine high dilution serum completely inhibits haemagglutination red blood cell . The titer antiserum show inhibition record &lt; 10 . Humoral response define either fourfold rise titer , rise non-protective baseline level &lt; 1/40 1/40 HI antibody four week vaccination 17,18 . Geometric mean titer antibody calculated ass immunity whole group . Primary Endpoint study : proportion patient achieve titer antibody 1/40 , antigen include vaccine Secondary Endpoint : Safety vaccine</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients &gt; 18 year old age Capable sign inform consent Suffering scleroderma Known allergy influenza vaccine Allergy egg</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>influenza vaccine scleroderma immunogenicity safety</keyword>
</DOC>